2024-09-06 17:16:02
The High Authority for Health (HAS) has issued favorable recommendations under the conditions for reimbursement by Health Insurance of the drug Mounjaro from the American pharmaceutical group Eli Lilly, authorized in the treatment of obesity a look type 2 diabetes. It’s a test these two twentyapproved in mid-July by the Committee that evaluates drugs, was made public on Friday September 6 on X.
In the treatment of obesity, the compensation of Mounjaro is guaranteed “only in addition to a low-calorie diet and increased physical activity for weight management”.
It is recommended that this treatment “Do the procedure only after advice from an expert in obesity management” in adults with an initial body mass index (BMI) greater than or equal to 35 kg/m² in the event of failure of well-designed nutritional management (less than 5% weight loss in six months). The committee also ruled “it is important to evaluate the effectiveness of the treatment after six months, and to consider a possible suspension, especially in the event of a weight loss of less than 5%”.
In the absence of strong comparative data compared to other GLP-1 analogues given in the treatment of obesity, Wegovy (semaglutide) or Saxenda (liraglutide), Mounjaro cannot be more important than these materials, HAS judges.
In type 2 diabetes, only Mounjaro treatment is recommended “In adults for uncontrolled treatment of type 2 diabetes in addition to diet and physical activity”etc “in 2nd or 3rd line of treatment”.
Mounjaro belongs to the class of drugs that mimic a gut hormone (GLP-1, short for glucagon-like peptide 1), which activates insulin secretion and provides a feeling of fullness.
These new generation drugs, which include Wegovy and Ozempic from the Danish Novo Nordisk, bring hope to millions of people because they can lead to greater weight loss than previous treatments. They are all the rage on social networks and generate astronomical profits for the pharmaceutical companies that sell them.
#High #Authority #Health #granted #reimbursement #Mounjaros #conditions